Osteoclasts and Bone Resorption

Key Osteoclast Concepts:

1. RANK/RANKL/OPG Axis: RANKL activates RANK receptor on precursors; OPG is decoy receptor
2. Ruffled Border: Specialized membrane creating acidic microenvironment (pH 4.5)
3. Sealing Zone: Actin ring isolates resorption compartment
4. Therapeutic Targets: Bisphosphonates (apoptosis), denosumab (RANKL inhibition)

The enzyme table and cheat sheet call TRAP "a serum marker of resorption", and Viva 3 asks which marker reflects osteoclast number — here are the resorption markers and what each actually measures.

Resorption markers fall rapidly when an antiresorptive is started (a CTX drop confirms response/compliance) and surge when denosumab is stopped — the biochemical signature of the rebound.

The osteopetrosis answer: in the common osteoclast-RICH forms (TCIRG1, CLCN7, carbonic anhydrase II — osteoclasts present but unable to resorb) TRAP-5b is HIGH because there are many osteoclasts; in the osteoclast-POOR RANK/RANKL forms it is LOW because osteoclasts fail to form. So TRAP-5b separates the two osteopetrosis subtypes and predicts whether haematopoietic stem cell transplantation can work. The bone-FORMATION markers (P1NP, osteocalcin, bone-specific ALP) and the remodeling cycle itself are developed in the osteoblasts-bone-formation and bone-remodeling topics.

The acidification tab notes that carbonic anhydrase II (CA-II) deficiency causes osteopetrosis "with renal tubular acidosis", and Viva 3 asks why — here is the mechanism. CA-II catalyses CO2 + H2O into H+ and bicarbonate, generating the very protons the osteoclast's H+-ATPase pumps into the resorption lacuna. The same enzyme is expressed in the renal tubule and the brain, so its autosomal-recessive loss produces a characteristic triad:

• Osteopetrosis — without CA-II-generated protons the osteoclast cannot acidify the lacuna or dissolve hydroxyapatite, so dense bone accumulates (the osteoclasts are present but non-functional).
• Renal tubular acidosis — CA-II is required for renal tubular acid-base handling, so its loss impairs both proximal bicarbonate reclamation and distal urinary acidification (a mixed, "type 3" RTA), producing a metabolic acidosis.
• Cerebral calcification (typically the basal ganglia) with developmental delay.

This renal-and-cerebral phenotype is what distinguishes CA-II deficiency from the TCIRG1 and CLCN7 acidification defects (which give isolated osteopetrosis); CA-II deficiency is also a milder, often later-presenting form. The detailed osteopetrosis subtypes and the role of HSCT are developed in the osteopetrosis topic.

When osteoclast number or function is abnormal, several conditions can present with overlapping radiographic or biochemical features. Distinguishing them rests on osteoclast biology.

Global Epidemiology

• Osteoporosis affects an estimated 500 million people worldwide; roughly 1 in 3 women and 1 in 5 men over 50 will sustain a fragility fracture.
• Over 8.9 million osteoporotic fractures occur globally each year (a fragility fracture roughly every 3 seconds), with hip fractures projected to rise sharply in Asia as populations age.
• Paget disease shows marked geographic variation — historically common in the UK and populations of British descent, and declining in prevalence in recent decades.
• Infantile (malignant) osteopetrosis has an incidence of approximately 1 in 250,000 births; the autosomal dominant adult form is far more common at around 1 in 20,000.

Major Guidelines, Side by Side

• Consensus across societies: nitrogen-containing bisphosphonates remain first-line; denosumab is a potent alternative but must never be stopped abruptly; teriparatide/romosozumab (anabolic) are favoured first for very-high-risk patients, followed by an anti-resorptive to consolidate gains.
• Anti-resorptive "drug holidays" apply to bisphosphonates (which persist in bone for years) but are explicitly contraindicated for denosumab.

Registry and Resource-Setting Notes

• Arthroplasty registries (NJR, AJRR, AOANJRR, SHAR, Norwegian, NZJR) track periprosthetic fractures, which are influenced by underlying bone quality and anti-resorptive status; bisphosphonate use around arthroplasty and its effect on aseptic loosening and revision is an area of ongoing analysis.
• In well-resourced settings, severe infantile osteopetrosis is managed with haematopoietic stem cell transplantation and bone-density-targeted pharmacotherapy is guided by DXA and bone turnover markers.
• In limited-resource settings, DXA access, the cost of denosumab and anabolic agents, and HSCT availability are major constraints; generic oral bisphosphonates and FRAX (which can be calculated without BMD) are the practical mainstays.

Osteoclasts are multinucleated (10-100 nuclei) bone-resorbing cells derived from the hematopoietic monocyte-macrophage lineage, fundamentally distinct from osteoblasts which arise from mesenchymal stem cells. The RANKL-RANK-OPG axis serves as the master regulatory pathway: RANKL from osteoblasts/stromal cells binds RANK on osteoclast precursors to drive differentiation, while osteoprotegerin (OPG) acts as a decoy receptor to inhibit this interaction. Active osteoclasts form a specialized ruffled border membrane that creates a sealed acidic microenvironment (pH 4.5) via H+-ATPase proton pumps to dissolve hydroxyapatite, with cathepsin K and matrix metalloproteinases degrading the organic matrix. This pathway is therapeutically targeted by bisphosphonates (induce osteoclast apoptosis via FPP synthase inhibition) and denosumab (RANKL monoclonal antibody) in osteoporosis management.